Tag: Johnson & Johnson
J&J launches “landmark” head-to-head pulsed field ablation trial in persistent AF
Johnson & Johnson (J&J) has announced the initiation of the PERSIGMA randomised controlled trial (RCT)—one of the first randomised studies evaluating competitive pulsed field...
J&J highlights favourable 12-month interim results on Varipulse platform at EHRA 2026
Johnson & Johnson (J&J) has announced favourable 12-month interim effectiveness and safety results from VARIPURE—the largest prospective post-market follow-up study evaluating first-time pulsed field ablation...
J&J launches new pulsed field ablation technology in Peru
Johnson & Johnson (J&J) has announced the arrival of a new pulsed field ablation (PFA) technology for the treatment of drug-refractory paroxysmal atrial fibrillation...
J&J presents early outcomes from OMNY-AF pilot study alongside new Varipulse...
Johnson & Johnson (J&J) has announced 12-month pilot-phase data from the OMNY-AF study evaluating its investigational Omnypulse platform for the treatment of symptomatic paroxysmal...
J&J MedTech presents new Omny-IRE and VARIPURE study data at HRS...
Johnson & Johnson (J&J) MedTech has announced positive initial three-month results from the Omny-IRE study evaluating the investigational Omnypulse platform in patients with paroxysmal...
J&J to resume Varipulse cases following ‘voluntary pause’ of US external...
Following a temporary, voluntary pause of US external evaluation and all US cases with its Varipulse catheter, Johnson & Johnson (J&J) is set to...
Cerenovus and Biosense Webster among brands newly incorporated into Johnson &...
Johnson & Johnson (J&J) recently shared that its medical technology businesses—including Cerenovus and Biosense Webster, as well as Abiomed, DePuy Synthes, and Ethicon—will now...
AF Symposium hears late-breaking data from RFA and PFA trials
Biosense Webster has announced an update and late-breaking data from trials across radiofrequency ablation (RFA) and pulsed field ablation (PFA) at the 2023 AF...
Biosense Webster announces first patients enrolled in post-market approval study for...
Johnson & Johnson have announced that Biosense Webster has received approval from the US Food and Drug Administration (FDA) for its VISITAG SURPOINT External...
New data demonstrates >90% year 1 success rate for radiofrequency ablation...
Biosense Webster, a Division of Johnson & Johnson Medical NV/SA, and a leader in the diagnosis and treatment of cardiac arrhythmias, recently presented new...